Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$76.27M
Enterprise ValueS$79.86M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recent Revenue ReboundA ~197% revenue rebound to ~5.3m in 2025 indicates renewed commercial traction and demand for diagnostic products. Sustained top-line growth over 2–6 months supports scaling, improves leverage potential on fixed costs, and validates go-to-market progress toward durable recurring sales.
Recurring Consumables Revenue ModelA consumables-driven model (test kits, reagents, repeat testing) creates recurring, high-frequency revenue tied to installed base. Over months this fosters predictable cash inflows, higher lifetime customer value, and margin expansion once fixed costs are covered, supporting long-term commercial stability.
Asset Base IncreasedRising total assets to ~5.1m provides a larger operational base for production, inventory, and receivables needed to support higher sales volumes. A larger asset base can underpin capacity expansion and distribution effectiveness, aiding durable commercial execution over coming months.
Bears Say
Persistent Negative Cash FlowNegative operating and free cash flow, even after improvement, means the company cannot self-fund operations and needs external financing or balance-sheet support. This structural cash burn constrains reinvestment, raises dilution or debt risk, and limits resilience to setbacks over months.
Meaningful Leverage, Thin Equity CushionElevated debt relative to a thin equity base and prior negative-equity periods reduce financial flexibility. With modest cushioning, the company faces refinancing risk and limited ability to absorb operating volatility, making sustained investment or weathering downturns more difficult.
Ongoing Losses And Volatile MarginsContinued sizable net losses and unstable margins despite revenue growth imply weak operating leverage or high fixed/variable costs. Without durable margin improvement, profitability remains distant, undermining free cash flow generation and the company’s ability to self-sustain growth longer term.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$76.27M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 34 days.
How were Biolidics Ltd.’s earnings last quarter?
Currently, no data Available
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business is structured into Cancer, Infectious Diseases, and Laboratory Services segments. The company's key innovations include the ClearCell FX1 System, an automated device that, using Streck Cell-free DNA BCT and EDTA tubes, isolates intact and viable circulating tumor cells (CTCs) from small blood samples. It also provides the CTChip FR1 biochip for separating CTCs from leukocytes, alongside offering general laboratory services. Established in 2009, the company was formerly known as Biolidics Limited, adopting its current name in June 2025.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―
Options Prices
Currently, No data available
---